^
HR positive + HER-2 negative
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
No biomarker
Male Breast Cancer
HER2 inhibitor
Sensitive: A2 - Guideline
HR positive + HER-2 negative
Male Breast Cancer
fulvestrant
Sensitive: A2 - Guideline
HR positive
Male Breast Cancer
Aromatase inhibitor
Sensitive: A2 - Guideline
HR positive
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
ER positive
Male Breast Cancer
tamoxifen
Sensitive: A2 - Guideline
PIK3CA mutation + HR positive + HER-2 negative
Male Breast Cancer
alpelisib
Sensitive: A2 - Guideline
HR positive + HER-2 negative
Male Breast Cancer
ribociclib
Sensitive: B - Late Trials
HR positive + HER-2 negative
Male Breast Cancer
palbociclib
Sensitive: C3 – Early Trials